Fiche publication
Date publication
novembre 2024
Journal
Bone marrow transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc
Tous les auteurs :
Mainguy A, Soussain C, Touitou V, Bennedjai A, Kodjikian L, Ghesquières H, Damaj G, Gressin R, Ducloyer JB, Chinot O, Vautier A, Moluçon-Chabrot C, Ahle G, Taillandier L, Marolleau JP, Chauchet A, Jardin F, Cassoux N, Malaise D, Toutée A, Touhami S, Le Garff-Tavernier M, Hoang-Xuan K, Choquet S, Houillier C
Lien Pubmed
Résumé
Despite its indolent evolution, vitreoretinal lymphoma (VRL) has a poor prognosis due to a major risk of relapse in the central nervous system (CNS) and may necessitate aggressive therapy. However, the use of high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is poorly documented. We retrospectively analysed from the French LOC network database the adult immunocompetent patients treated with HCT-ASCT for isolated VRL. Thirty-eight patients underwent consolidation with HCT-ASCT for isolated VRL between 2008 and 2019 after induction chemotherapy. Twenty patients had primary VRL, and 18 had an isolated VRL relapse of a primary CNS lymphoma. Three patients underwent HCT-ASCT in first-line treatment, 24 in second-line treatment, and 11 in subsequent lines. At HCT-ASCT, the median age was 61 years, and the median KPS was 90. Thirty-two patients (84%) received high-dose thiotepa-based HCT. One patient (3%) died from HCT-ASCT toxicity. Nineteen (50%) patients relapsed after HCT-ASCT, including 17 cases occurring in the brain. The median progression-free survival, brain-free survival and overall survival from HCT-ASCT were 96, 113 and 92 months, respectively. HCT-ASCT represents an effective therapeutic strategy for select VRL patients, with a tolerable safety profile. However, the risk of subsequent brain relapse remains significant.
Référence
Bone Marrow Transplant. 2024 11 19;:
